---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033580"
form_type: "8-K"
ticker: "STE"
cik: "0001757898"
company_name: "STERIS plc"
filed_at: "2026-05-11T20:34:04+00:00"
generated_at: "2026-05-11T20:36:33.923772+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# STERIS FY26 revenue $5.9B (+9%), adj EPS $10.17; FY27 guidance adj EPS $11.10-$11.30

## Summary
- Full year revenue from continuing ops $5.9B (+9%), constant currency organic +7%; adjusted EPS $10.17 vs $9.22.
- Q4 revenue $1.6B (+7%), adjusted EPS $2.83 vs $2.74; Healthcare rev $1.14B (+7%), AST $289.2M (+6%), Life Sci $162.9M (+9%).
- FY26 operating cash flow $1.34B, free cash flow $982.9M (up from $787.2M).
- FY27 guidance: revenue +7-8%, organic +6-7%, adj EPS $11.10-$11.30 (9-11% growth), capex ~$375M, FCF ~$850M.
- Board authorized new $1B share repurchase program; $60M strategic investment for new sterility plant in Mentor, Ohio (operational late CY2027).

## SEC filing metadata
- accession: 0001628280-26-033580
- form_type: 8-K
- ticker: STE
- cik: 0001757898
- company_name: STERIS plc
- filed_at: 2026-05-11T20:34:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/0001628280-26-033580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/ste-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033580
- JSON: https://secwatch.observer/filing/0001628280-26-033580.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033580.txt

## Key facts
- Earnings Releases
  STERIS plc reported the twelve months ended March 31, 2026 results: revenue $5.9 billion, net income $782.3 million or $7.93 per diluted share. Guidance raised.
  - Period: the twelve months ended March 31, 2026
  - Revenue: $5.9 billion
  - Net income: $782.3 million or $7.93 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: currency organic revenue growth from continuing operations grew 5% in the fourth quarter. Revenue from continuing operations for the full year fiscal 2026 increased 9% to $5.9 billion compared with $5.5 billion in fiscal 2025. Constant currency organic revenue growth from continuing operations grew 7% for fiscal 2026. “Fiscal 2026 was another record year,”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/0001628280-26-033580-index.htm
- Earnings Releases
  STERIS plc reported the three months ended March 31, 2026 results: revenue $1.6 billion, net income $220.3 million or $2.24 per diluted share.
  - Period: the three months ended March 31, 2026
  - Revenue: $1.6 billion
  - Net income: $220.3 million or $2.24 per diluted share
  - Result: reported results
  source text: Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/0001628280-26-033580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.